Jamming the transmission

With the current focus of the public equity markets on biotechnology companies that have profits from product sales, startup companies with an eye towards staying independent must convince investors that their technology will lead to products.

Message Pharmaceuticals Inc.'s SCRIBE technology has utility across a variety of diseases.

SCRIBE (Specific Control of RNA Interactions and Binding Events) modulates the expression of disease-associated genes by altering interactions between messenger RNA (mRNA) and RNA-binding proteins. The company looks for RNA motifs in